Protalix BioTherapeutics (PLX) EBITDA Margin Growth (3y) (2013 - 2026)
Protalix BioTherapeutics (PLX) EBITDA Margin Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | -377.00 |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | -204.00 |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | -537.00 |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | -1,934.00 |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 7,261.00 |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | 9,003.00 |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | -11,254.00 |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 30,461.00 |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | -2,649.00 |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn | -3,408.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,474.00 |
| Mar 31, 2026 | 8,830.00 |
| Dec 31, 2025 | -2,211.00 |
| Sep 30, 2025 | 3,397.00 |
| Jun 30, 2025 | 7,059.00 |
| Mar 31, 2025 | -2,936.00 |
| Dec 31, 2024 | 10,632.00 |
| Sep 30, 2024 | 3,786.00 |
| Jun 30, 2024 | 12,460.00 |
| Mar 31, 2024 | -9,683.00 |
| Dec 31, 2023 | -6,811.00 |
| Sep 30, 2023 | 569.00 |
| Jun 30, 2023 | 7,865.00 |
| Mar 31, 2023 | -4,733.00 |
| Dec 31, 2022 | -4,469.00 |
| Sep 30, 2022 | -1,120.00 |
| Jun 30, 2022 | -1,543.00 |
| Mar 31, 2022 | 4,139.00 |
| Dec 31, 2021 | 14,237.00 |
| Sep 30, 2021 | 54,862.00 |